Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B16dcc3aa1ff2fb98b3049421c0bc773c> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B16dcc3aa1ff2fb98b3049421c0bc773c NCIT_P378 "NCI" @default.
- B16dcc3aa1ff2fb98b3049421c0bc773c type Axiom @default.
- B16dcc3aa1ff2fb98b3049421c0bc773c annotatedProperty IAO_0000115 @default.
- B16dcc3aa1ff2fb98b3049421c0bc773c annotatedSource NCIT_C1010 @default.
- B16dcc3aa1ff2fb98b3049421c0bc773c annotatedTarget "A pyrazolinone derivative with potential antimetastatic activities. Nafazatrom, originally developed as an antithrombotic agent, inhibits the key prostaglandin catabolic enzyme, 15-hydroxyprostaglandin dehydrogenase, which prolongs the biological half-life of prostacyclin (prostaglandin I2; PGI2) and prevents intravascular coagulation. This agent also serves as a reducing cofactor with the hydroperoxidase moiety of cyclooxygenase and accelerates the conversion of arachidonic acid into precursors of PGI2. An elevated level of PGI2 prevents aggregation of platelets; subsequently it decreases the formation of tumor cell-platelet aggregates as well as their sequestration in blood vessels, which is an important initiating step in the development of metastasis." @default.